Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.77 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16552344 | 0.87 | MAOB (1.00) | MAOBMAOAFFAR1 | |
| SCHEMBL17923867 | 0.87 | MAOB (1.00) | MAOBMAOAFFAR1 | |
| SCHEMBL17935575 | 0.83 | MAOB (0.57) | MAOB | |
| SCHEMBL17931624 | 0.83 | MAOB (0.55) | MAOB | |
| SCHEMBL17931589 | 0.82 | MAOB (0.75) | MAOBMAOAFFAR1 | |
| SCHEMBL17923857 | 0.81 | MAOB (0.71) | MAOBMAOAFFAR1S1PR1HTR2A | |
| SCHEMBL17931623 | 0.81 | MAOB (0.52) | MAOB | |
| SCHEMBL16552387 | 0.73 | MAOB (1.00) | MAOBMAOA | |
| SCHEMBL17923834 | 0.73 | MAOB (1.00) | MAOBMAOA | |
| SCHEMBL16552365 | 0.72 | MAOB (0.41) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3039009-B1 | MAO-B SELECTIVE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | UNIV BRITISH COLUMBIA (CA) | 2019-05-01 | — | — | EP | disclosed |
| US-10196345-B2 | MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-02-05 | — | — | US | disclosed |
| US-20160207878-A1 | MAO-B Selective Inhibitor Compounds, Pharmaceutical Compositions Thereof and Uses Thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-21 | — | — | US | disclosed |
| US-20160207878-A1 | MAO-B Selective Inhibitor Compounds, Pharmaceutical Compositions Thereof and Uses Thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-21 | — | — | US | disclosed |
| US-20160207878-A1 | MAO-B Selective Inhibitor Compounds, Pharmaceutical Compositions Thereof and Uses Thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-21 | — | — | US | disclosed |
| WO-2015027324-A1 | MAO-B SELECTIVE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196345-B2 | MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof | MAOB, MAOA, COMT | MAOB 1/4885MAOA 2/4885FFAR1 757/4885 |
| US-20160207878-A1 | MAO-B Selective Inhibitor Compounds, Pharmaceutical Compositions Thereof and Uses Thereof | MAOB, MAOA, COMT | MAOB 1/4885MAOA 2/4885FFAR1 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.